CVAS-an interesting california-based biotech company here

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
CVAS-an interesting california-based biotech company here

An SI Board Since September 1999

Posts	SubjectMarks	Bans	Symbol
126	13	0	CVAS

Emcee: kendall harmon	Type: Unmoderated

Introduction Market Data Compact

CVAS--Corvas International, Inc. designs and develops therapeutic agents for cardiovascular, cancer, and other major diseases. The Company has an alliance with Pfizer Inc. to develop neutrophil inhibitory factor as possible stroke therapy. Corvas also has an alliance with Schering-Plough Corporation to develop an oral anticoagulant for chronic cardiovascular disease.

This stock has come up on a few scans recently, and I am wondering if perhaps it may garner some interest in the midst of an overall resurgence of the biotech sector.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
126	Nuvelo Licenses rNAPc2, a Novel Anticoagulant, From Dendreon Wednesday February	keokalani'nui	-	2/4/2004
125	Today there was spike in CVAS/DNDN after hour volume, and rise in stock price. F	Miljenko Zuanic	-	7/9/2003
124	WSJ article on Dendritic cells based cancer vaccines. Interesting that DNA/DNDN	Miljenko Zuanic	-	5/24/2003
123	Stumbled across this in the '03 AACR abstracts: >>Anti-tumor activity	tuck	-	3/20/2003
122	How much is NAPc2 worth after successful (???) first phase of the PII trial? We	Miljenko Zuanic	-	3/15/2003
121	<i>which we view as certain to fail in a shareholder vote</i> Now t	tom pope	-	3/6/2003
120	SC Fundamental Urges Corvas International to Stop Spending, Cancel Merger, and L	keokalani'nui	-	3/6/2003
119	Dendreon Corporation Reports Fourth Quarter and Year End 2002 Financial Results	nigel bates	-	3/6/2003
118	<<Lampert 100% right IMO.>> Lampert is thinking only about his pock	Miljenko Zuanic	-	3/5/2003
117	Brilliant!	keokalani'nui	-	3/5/2003
116	MLNM might have made a more interesting fit ? The ceo could then use whatever s	nigel bates	-	3/5/2003
115	Lampert 100% right IMO. Corvas CEO should not make the decision for cvas shareh	keokalani'nui	-	3/5/2003
114	Shareholders best interest, or his and his patatoes severance package interest (	Miljenko Zuanic	-	3/4/2003
113	Biotech Grp: Corvas-Dendreon Deal Not In Hldrs Interests Monday March 3, 6:02 pm	keokalani'nui	-	3/3/2003
112	<pre> Balance Sheet Data: Decembe	nigel bates	-	2/27/2003
111	IF Provenge work in HRPC than this merge does make sense. On the other hand, CVA	Miljenko Zuanic	-	2/25/2003
110	Dendreon To Acquire Corvas Message 18624335	michael_f_murphy	-	2/25/2003
109	Article on rNAPc2. Nothing new, just a convenient aggregation of info for those	tuck	-	12/21/2002
108	Thanks WE. This PIa/b trial was part of the IND for PII trial, swing from SC to	Miljenko Zuanic	-	12/3/2002
107	ASH Preview Dr. Leon Henderson will be attending the American Society of Hemat	keokalani'nui	-	12/3/2002
106	It sound like very optimistic plan for PII. First phase should be completed fair	Miljenko Zuanic	-	11/5/2002
105	>>SAN DIEGO, Nov. 5 /PRNewswire-FirstCall/ -- Corvas International, Inc. (	tuck	-	11/5/2002
104	Biotech Value Fund Ups Corvas Stake To 19.4% From 17.7% DOW JONES NEWSWIRES WA	mopgcw	-	9/29/2002
103	Corvas solidly in roach motel land. At some point in the remaining months of th	tuck	-	9/11/2002
102	Corvas Restructures Workforce; Company to Focus Resources on Most Advanced Progr	nigel bates	-	7/23/2002

Go to reply# or date (mm/dd/yy):